|http://ghr.nlm.nih.gov/ A service of the U.S. National Library of Medicine®|
The official name of this gene is “collagen, type I, alpha 1.”
COL1A1 is the gene's official symbol. The COL1A1 gene is also known by other names, listed below.
The COL1A1 gene provides instructions for making part of a large molecule called type I collagen. Collagens are a family of proteins that strengthen and support many tissues in the body, including cartilage, bone, tendon, skin, and the white part of the eye (the sclera). Type I collagen is the most abundant form of collagen in the human body.
The COL1A1 gene produces a component of type I collagen called the pro-α1(I) chain. Collagens begin as procollagen molecules, which must be processed by enzymes outside the cell to remove extra protein segments from their ends. Each rope-like procollagen molecule is made up of three chains: two pro-α1(I) chains, which are produced from the COL1A1 gene, and one pro-α2(I) chain, which is produced from the COL1A2 gene.
After procollagens are processed, the resulting mature collagen molecules arrange themselves into long, thin fibrils. Individual collagen molecules are cross-linked to one another within these fibrils. The formation of cross-links results in very strong type I collagen fibrils, which are found in the spaces around cells.
The COL1A1 gene belongs to a family of genes called COL (collagens).
A gene family is a group of genes that share important characteristics. Classifying individual genes into families helps researchers describe how genes are related to each other. For more information, see What are gene families? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genefamilies) in the Handbook.
A mutation in the COL1A1 gene causes infantile cortical hyperostosis, commonly known as Caffey disease. The signs and symptoms of Caffey disease are usually apparent by the time an infant is 5 months old. This condition is characterized by swelling of soft tissues (muscles, for example), pain, and excessive new bone formation (hyperostosis). The bone abnormalities mainly affect the jawbone, collarbones (clavicles), and the shafts (diaphyses) of long bones in the arms and legs. For unknown reasons, the pain and swelling associated with Caffey disease typically go away within a few months. Through a normal process called bone remodeling, which replaces old bone tissue with new bone, the excess bone is usually reabsorbed by the body and undetectable on x-ray images by the age of 2. The mutation responsible for this condition replaces the protein building block (amino acid) arginine with the amino acid cysteine at protein position 836 (written as Arg836Cys or R836C). This mutation results in the production of type I collagen fibrils that are variable in size and shape, but it is unknown how these changes lead to the signs and symptoms of Caffey disease.
Several mutations in the COL1A1 gene are responsible for the arthrochalasia type of Ehlers-Danlos syndrome. These genetic changes lead to the production of a pro-α1(I) chain that is missing a critical segment. The absence of this segment interferes with the assembly and structure of type I collagen molecules and the processing of these molecules into collagen fibrils. Tissues that are rich in type I collagen, such as the skin, bones, and tendons, are most affected by this change.
A mutation in the COL1A1 gene has also been shown to cause the classic type of Ehlers-Danlos syndrome. This mutation changes one of the amino acids used to build the pro-α1(I) chain. Specifically, this genetic change replaces the amino acid arginine with the amino acid cysteine at position 134 (written as Arg134Cys or R134C). The altered protein interferes with other collagen-building proteins, disrupting the structure of type I collagen fibrils and trapping collagen in the cell. Researchers believe that this COL1A1 mutation only rarely underlies the signs and symptoms of classic Ehlers-Danlos syndrome.
Osteogenesis imperfecta is the most common disorder caused by mutations in the COL1A1 gene. More than 400 COL1A1 gene mutations that cause osteogenesis imperfecta have been identified. Most of the mutations that are responsible for osteogenesis imperfecta type I, the mildest form of this disorder, reduce the production of pro-α1(I) chains. With fewer pro-α1(I) chains available, cells can make only half the normal amount of type I collagen. A shortage of this critical protein underlies the bone fragility and other characteristic features of osteogenesis imperfecta type I.
Several kinds of mutations in the COL1A1 gene cause the more severe forms of osteogenesis imperfecta, including types II, III, and IV. In addition to more severe bone problems, features of these conditions can include blue sclerae, short stature, hearing loss, respiratory problems, and a disorder of tooth development called dentinogenesis imperfecta. Some of the mutations that cause severe forms of osteogenesis imperfecta delete segments of DNA from the COL1A1 gene, resulting in an abnormally shortened, often nonfunctional pro-α1(I) chain. Other genetic changes alter the sequence of amino acids in the pro-α1(I) chain, usually replacing the amino acid glycine with a different amino acid. In some cases, amino acid substitutions alter one end of the protein chain (called the C-terminus), which interferes with the assembly of collagen molecules. These COL1A1 gene mutations lead to the production of abnormal versions of type I collagen. When this abnormal collagen is incorporated into developing bones and other connective tissues, it causes the serious health problems associated with severe forms of osteogenesis imperfecta.
Dermatofibrosarcoma protuberans, a rare type of cancer that causes a tumor in the deep layers of the skin, is characterized by a somatic mutation involving the COL1A1 gene. Somatic mutations are not inherited, but are acquired during a person's lifetime and present only in certain cells. Dermatofibrosarcoma protuberans is associated with a rearrangement (translocation) of genetic material between chromosomes 17 and 22. This translocation, written as t(17;22), fuses part of the COL1A1 gene on chromosome 17 with part of a gene on chromosome 22 called PDGFB. This translocation is found on one or more extra chromosomes that can be either the normal linear shape or circular.
The fused COL1A1-PDGFB gene provides instructions for making a combined (fusion) protein that researchers believe ultimately functions like the active PDGFB protein. In the translocation, the PDGFB gene loses the part of its DNA that limits its activity, and production of the COL1A1-PDGFB fusion protein is controlled by COL1A1 gene sequences. As a result, the gene fusion leads to the production of a larger amount of active PDGFB protein than normal. Active PDGFB protein signals for cell growth and division (proliferation) and maturation (differentiation). Excess PDGFB protein abnormally stimulates cells to proliferate and differentiate, leading to the tumor formation seen in dermatofibrosarcoma protuberans.
Some people with COL1A1 mutations exhibit the signs and symptoms of both osteogenesis imperfecta and Ehlers-Danlos syndrome. These mutations replace the amino acid glycine with a different amino acid in the pro-α1(I) chain, which impairs the interactions between protein chains. The resulting abnormal type I collagen fibrils weaken connective tissue, causing the signs and symptoms associated with these two conditions.
A common variation in the COL1A1 gene (called a polymorphism) appears to increase the risk of developing osteoporosis. Osteoporosis is a condition that makes bones progressively more brittle and prone to fracture. This polymorphism, which occurs in a regulatory region of the COL1A1 gene, likely affects the production of type I collagen. Several studies have shown that women with this genetic change are more likely to have signs of osteoporosis, particularly low bone density and bone fractures, than are women without the change. This variation is only one of many factors that can increase the risk of osteoporosis.
Cytogenetic Location: 17q21.33
Molecular Location on chromosome 17: base pairs 50,184,095 to 50,201,647
The COL1A1 gene is located on the long (q) arm of chromosome 17 at position 21.33.
More precisely, the COL1A1 gene is located from base pair 50,184,095 to base pair 50,201,647 on chromosome 17.
See How do geneticists indicate the location of a gene? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genelocation) in the Handbook.
You and your healthcare professional may find the following resources about COL1A1 helpful.
You may also be interested in these resources, which are designed for genetics professionals and researchers.
See How are genetic conditions and genes named? (http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/naming) in the Handbook.
acids ; amino acid ; arginine ; bone density ; bone formation ; bone remodeling ; cancer ; cartilage ; cell ; chromosome ; collagen ; connective tissue ; cysteine ; dentinogenesis ; differentiation ; DNA ; gene ; glycine ; hyperostosis ; inherited ; molecule ; mutation ; osteogenesis ; osteoporosis ; polymorphism ; Pro ; proliferate ; proliferation ; protein ; rearrangement ; respiratory ; sclera ; short stature ; somatic mutation ; stature ; syndrome ; tendon ; tissue ; translocation ; tumor
You may find definitions for these and many other terms in the Genetics Home Reference Glossary (/glossary).
The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.